



SAFETY DATA SHEET

Revision date: 02-Feb-2016

Version: 1.1

Page 1 of 24

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: CENTRUM Men Tablets

Trade Name: CENTRUM
Compound Number: WH-1683-0001
Synonyms: Centrum Men Tablets (1000 IU Vit. D, Project Zoom); Centrum Adult Ultra Men
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Consumer healthcare product used as dietary supplement

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
1 Giralda Farms
Madison, NJ 07940

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

Note: No data available
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%

SAFETY DATA SHEET

Material Name: **CENTRUM Men Tablets**
Revision date: **02-Feb-2016**

Page **2** of **24**
Version: **1.1**

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ferrous fumarate	141-01-5	205-447-7	Not Listed	*
Ascorbic acid (Vitamin C)	50-81-7	200-066-2	Not Listed	*
Butylated hydroxytoluene	128-37-0	204-881-4	Not Listed	*
Calcium carbonate	471-34-1	207-439-9	Not Listed	*
Cholecalciferol (Vitamin D3)	67-97-0	200-673-2	Acute Tox. 3 (H301) Acute Tox. 3 (H311) STOT RE 1 (H372) Acute Tox. 2 (H330)	<0.01
Corn Starch	9005-25-8	232-679-6	Not Listed	*
Cupric sulfate	7758-98-7	231-847-6	Acute Tox. 4 (H302) Skin Irrit. 2 (H315) Aquatic Chronic 1 (H410) Aquatic Acute 1 (H400) Eye Irrit. 2 (H319)	0.19
Cyanocobalamin (Vitamin B12)	68-19-9	200-680-0	Not Listed	*
Dicalcium Phosphate	7757-93-9	231-826-1	Not Listed	*
Stannous Chloride	10025-69-1	Not Listed	Not Listed	*
Folic Acid	59-30-3	200-419-0	Not Listed	*
Polyethylene glycol	25322-68-3	Not Listed	Not Listed	*
Magnesium oxide	1309-48-4	215-171-9	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*
Manganese sulfate	7785-87-7	232-089-9	STOT RE 2 (H373) Aquatic Chronic 2 (H411)	0.5
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Niacinamide	98-92-0	202-713-4	Not Listed	*
Nickel sulphate	10101-97-0	Not Listed	Acute Tox. 4 (H302) STOT RE 1 (H372) Muta. 2 (H341) Repr. 1B (H360D) Skin Irrit. 2 (H315) Carc. 1A (H350i) Acute Tox. 4 (H332)	<0.01
Phytonadione (Vit.K)	84-80-0	201-564-2	Not Listed	*
Potassium Iodide	7681-11-0	231-659-4	Not Listed	*
Riboflavin (Vitamin B2)	83-88-5	201-507-1	Not Listed	*
Silicon dioxide, NF	7631-86-9	231-545-4	Not Listed	*
Sodium Metavanadate	13718-26-8	237-272-7	Not Listed	*
Sodium Molybdate	7631-95-0	231-551-7	Not Listed	*
Sodium Selenate	13410-01-0	236-501-8	Acute Tox. 3 (H301) STOT RE 2 (H373) Acute Tox. 3 (H331)	<0.1
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	*
Vitamin A Acetate	127-47-9	204-844-2	Not Listed	*
Zinc oxide	1314-13-2	215-222-5	Aquatic Chronic 1 (H410) Aquatic Acute 1 (H400)	1

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Maltodextrin	9050-36-6	232-940-4	Not Listed	*
Beta Carotene	7235-40-7	230-636-6	Not Listed	*
Biotin	58-85-5	200-399-3	Not Listed	*
Calcium pantothenate	137-08-6	205-278-9	Not Listed	*
POTASSIUM CHLORIDE	7447-40-7	231-211-8	Not Listed	*

SAFETY DATA SHEET

Material Name: **CENTRUM Men Tablets**
Revision date: **02-Feb-2016**

Page **3** of **24**
Version: **1.1**

Chromium picolinate	27882-76-4	Not Listed	Not Listed	*
Crospovidone	9003-39-8	Not Listed	Not Listed	*
Polyvinyl alcohol	9002-89-5	Not Listed	Not Listed	*
FD & C Red No. 40, aluminum lake	68583-95-9	271-524-7	Not Listed	*
FD&C yellow No.6 aluminum lake	15790-07-5	239-888-1	Not Listed	*
Gelatin	9000-70-8	232-554-6	Not Listed	*
Hydrogenated Palm Oil	68514-74-9	271-056-3	Not Listed	*
Lecithin	8002-43-5	232-307-2	Not Listed	*
Lycopene	502-65-8	207-949-1	Not Listed	*
Pyridoxine Hydrochloride (Vitamin B6)	58-56-0	200-386-2	Not Listed	*
Sodium ascorbate	134-03-2	205-126-1	Not Listed	*
Thiamine Mononitrate	532-43-4	208-537-4	Not Listed	*
Tocopherols	1406-66-2	Not Listed	Not Listed	*
Vitamin E, dl-tocopheryl acetate	52225-20-4	257-757-7	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: No data available

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 4 of 24
Version: 1.1

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Consumer healthcare product used as dietary supplement

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Ferrous fumarate

ACGIH Threshold Limit Value (TWA) 1 mg/m³

Butylated hydroxytoluene

ACGIH Threshold Limit Value (TWA)	2 mg/m ³
Australia TWA	10 mg/m ³
Austria OEL - MAKs	10 mg/m ³
Belgium OEL - TWA	2 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Denmark OEL - TWA	10 mg/m ³
Finland OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Germany - TRGS 900 - TWAs	10 mg/m ³
Germany (DFG) - MAK	10 mg/m ³
Greece OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
Portugal OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	10 mg/m ³

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 5 of 24
Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Calcium carbonate

Australia TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
France OEL - TWA	10 mg/m ³
Latvia OEL - TWA	6 mg/m ³
Poland OEL - TWA	10 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Vietnam OEL - TWAs	10 mg/m ³

POTASSIUM CHLORIDE

Bulgaria OEL - TWA	5.0 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	5 mg/m ³

Corn Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³

Cupric sulfate

ACGIH Threshold Limit Value (TWA)	1 mg/m ³
Finland OEL - TWA	1 mg/m ³
Russia OEL - TWA	0.5 mg/m ³

Dicalcium Phosphate

Latvia OEL - TWA	10 mg/m ³
------------------	----------------------

Stannous Chloride

ACGIH Threshold Limit Value (TWA)	2 mg/m ³
Finland OEL - TWA	2 mg/m ³

Polyethylene glycol

Austria OEL - MAKs	1000 mg/m ³
Germany - TRGS 900 - TWAs	1000 mg/m ³
Germany (DFG) - MAK	1000 mg/m ³ average molecular weight 200-600
Slovakia OEL - TWA	1000 mg/m ³
Slovenia OEL - TWA	1000 mg/m ³
Switzerland OEL - TWAs	1000 ppm

Magnesium oxide

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 6 of 24
Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Austria OEL - MAKs	5 mg/m ³ 10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	5 mg/m ³
Denmark OEL - TWA	6 mg/m ³
France OEL - TWA	10 mg/m ³
Germany (DFG) - MAK	1.5 mg/m ³ 4 mg/m ³
Greece OEL - TWA	10 mg/m ³ 5 mg/m ³
Hungary OEL - TWA	6 mg/m ³
Ireland OEL - TWAs	4 mg/m ³ 5 mg/m ³ 10 mg/m ³
Lithuania OEL - TWA	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	5 mg/m ³ 10 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	5 mg/m ³
Slovakia OEL - TWA	1.5 mg/m ³ 4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³
Magnesium stearate	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³
Manganese sulfate	
ACGIH Threshold Limit Value (TWA)	0.02 mg/m ³ 0.1 mg/m ³
Finland OEL - TWA	0.2 mg/m ³
Microcrystalline cellulose	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³ 4 mg/m ³
Latvia OEL - TWA	2 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Russia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 7 of 24
Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Switzerland OEL - TWAs	3 mg/m ³
Vietnam OEL - TWAs	10 mg/m ³
	5 mg/m ³
Niacinamide	
Latvia OEL - TWA	1 mg/m ³
Lithuania OEL - TWA	1 mg/m ³
Nickel sulphate	
ACGIH Threshold Limit Value (TWA)	0.1 mg/m ³
Potassium Iodide	
ACGIH Threshold Limit Value (TWA)	0.01 ppm
Bulgaria OEL - TWA	5.0 mg/m ³
Riboflavin (Vitamin B2)	
Latvia OEL - TWA	1 mg/m ³
Lithuania OEL - TWA	1 mg/m ³
Silicon dioxide, NF	
Australia TWA	2 mg/m ³
Austria OEL - MAKs	4 mg/m ³
	0.3 mg/m ³
Czech Republic OEL - TWA	0.1 mg/m ³
	4.0 mg/m ³
Estonia OEL - TWA	2 mg/m ³
Finland OEL - TWA	5 mg/m ³
Germany - TRGS 900 - TWAs	4 mg/m ³
Germany (DFG) - MAK	4 mg/m ³
Ireland OEL - TWAs	6 mg/m ³
	2.4 mg/m ³
Latvia OEL - TWA	1 mg/m ³
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
	Listed
Slovakia OEL - TWA	4.0 mg/m ³
Switzerland OEL - TWAs	4 mg/m ³
	0.3 mg/m ³
Sodium Molybdate	
ACGIH Threshold Limit Value (TWA)	0.5 mg/m ³
Sodium Selenate	
ACGIH Threshold Limit Value (TWA)	0.2 mg/m ³
Talc (non-asbestiform)	
ACGIH Threshold Limit Value (TWA)	2 mg/m ³
Australia TWA	2.5 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Belgium OEL - TWA	2 mg/m ³
Bulgaria OEL - TWA	1.0 fiber/cm ³
	6.0 mg/m ³
	3.0 mg/m ³
Czech Republic OEL - TWA	2.0 mg/m ³

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 8 of 24
Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Denmark OEL - TWA	0.3 fiber/cm ³
Finland OEL - TWA	0.5 fiber/cm ³
Greece OEL - TWA	10 mg/m ³
	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	0.8 mg/m ³
Lithuania OEL - TWA	2 mg/m ³
	1 mg/m ³
Netherlands OEL - TWA	0.25 mg/m ³
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
Poland OEL - TWA	4.0 mg/m ³
	1.0 mg/m ³
Portugal OEL - TWA	2 mg/m ³
Romania OEL - TWA	2 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
	10 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Spain OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	2 mg/m ³
	1 mg/m ³
Switzerland OEL -TWAs	2 mg/m ³

Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
ACGIH OELs - Notice of Intended Changes	Listed
Australia TWA	10 mg/m ³
Austria OEL - MAKs	5 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Denmark OEL - TWA	6 mg/m ³
Estonia OEL - TWA	5 mg/m ³
France OEL - TWA	10 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
Latvia OEL - TWA	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	10.0 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Russia OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Sweden OEL - TWAs	5 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³
Vietnam OEL - TWAs	6 mg/m ³
	5 mg/m ³

Zinc oxide

ACGIH Threshold Limit Value (TWA)	2 mg/m ³
ACGIH Threshold Limit Value (STEL)	10 mg/m ³

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 9 of 24
Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Australia STEL	10 mg/m ³
Australia TWA	10 mg/m ³
	5 mg/m ³
Austria OEL - MAKs	5 mg/m ³
Belgium OEL - TWA	10 mg/m ³
	5 mg/m ³
Bulgaria OEL - TWA	5.0 mg/m ³
Czech Republic OEL - TWA	2 mg/m ³
Denmark OEL - TWA	4 mg/m ³
Estonia OEL - TWA	5 mg/m ³
Finland OEL - TWA	2 mg/m ³
France OEL - TWA	5 mg/m ³
	10 mg/m ³
Germany (DFG) - MAK	1 mg/m ³
Greece OEL - TWA	5 mg/m ³
Hungary OEL - TWA	5 mg/m ³
Ireland OEL - TWAs	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
OSHA - Final PELs - TWAs:	5 mg/m ³
	15 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	2 mg/m ³
Romania OEL - TWA	5 mg/m ³
Russia OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	1 mg/m ³
Slovenia OEL - TWA	5 mg/m ³
Spain OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	5 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

Ascorbic acid (Vitamin C)

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Cholecalciferol (Vitamin D3)

Pfizer Occupational Exposure Band (OEB): OEB 5 (control exposure to <1ug/m³)

Folic Acid

Pfizer Occupational Exposure Band (OEB): OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures.
Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 10 of 24
Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	Color:	Orange
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Butylated hydroxytoluene

No data available

Riboflavin (Vitamin B2)

No data available

Stannous Chloride

No data available

Calcium carbonate

No data available

Microcrystalline cellulose

No data available

Magnesium oxide

No data available

POTASSIUM CHLORIDE

No data available

Ascorbic acid (Vitamin C)

No data available

Dicalcium Phosphate

No data available

Maltodextrin

No data available

Vitamin E, dl-tocopheryl acetate

No data available

Corn Starch

No data available

Ferrous fumarate

No data available

Crospovidone

No data available

Calcium pantothenate

No data available

Niacinamide

No data available

Polyvinyl alcohol

No data available

Zinc oxide

No data available

Manganese sulfate

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 11 of 24
Version: 1.1

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

Talc (non-asbestiform)

No data available

Titanium dioxide

No data available

Silicon dioxide, NF

No data available

Polyethylene glycol

No data available

Gelatin

No data available

Magnesium stearate

No data available

Pyridoxine Hydrochloride (Vitamin B6)

No data available

Cupric sulfate

No data available

Thiamine Mononitrate

No data available

Vitamin A Acetate

No data available

Lecithin

No data available

Beta Carotene

No data available

Sodium ascorbate

No data available

FD&C yellow No.6 aluminum lake

No data available

Folic Acid

No data available

Tocopherols

No data available

Potassium Iodide

No data available

Sodium Molybdate

No data available

Phytonadione (Vit.K)

No data available

Biotin

No data available

FD & C Red No. 40, aluminum lake

No data available

Cholecalciferol (Vitamin D3)

No data available

Sodium Metavanadate

No data available

Cyanocobalamin (Vitamin B12)

No data available

Sodium Selenate

No data available

Decomposition Temperature (°C): No data available.

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 12 of 24
Version: 1.1

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: An Occupational Exposure Limit has been established for one or more of the ingredients (see Section 8). Dust may cause irritation if tablets are crushed or broken
Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including gastrointestinal irritation

Acute Toxicity: (Species, Route, End Point, Dose)

Butylated hydroxytoluene

Rat Oral LD50 1700 mg/kg
Mouse Oral LD50 650 mg/kg
Rat Oral LD50 890 mg/kg
Mouse Intraperitoneal LD 50 138 mg/kg

Calcium carbonate

Rat Oral LD50 6450 mg/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

POTASSIUM CHLORIDE

Rat Oral LD50 2600 mg/kg

SAFETY DATA SHEET

Material Name: **CENTRUM Men Tablets**
Revision date: **02-Feb-2016**

Page 13 of 24
Version: 1.1

11. TOXICOLOGICAL INFORMATION

Ascorbic acid (Vitamin C)

Rat Oral LD 50 11.9 g/kg

Zinc oxide

Mouse Oral LD50 7950 mg/kg
Rat IP LD50 240mg/kg
Mouse Inhalation LD50 2500mg/m³
Rat Oral LD 50 >5000mg/kg

Manganese sulfate

Rat Oral LD50 2150 mg/kg

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg
Rat Subcutaneous LD50 50 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Cupric sulfate

Rat Oral LD50 300 mg/kg
Rabbit Dermal LD 50 1000mg/kg

Lecithin

Rat Oral LD50 > 8 ml/kg

Folic Acid

Mouse Oral LD 50 10 g/kg

Sodium Molybdate

Rat Oral LD50 4000 mg/kg

Cholecalciferol (Vitamin D3)

Rat Oral LD50 42 mg/kg
Mouse Sub-tenon injection (eye) LD 50 136 mg/kg
Rat Inhalation LC50/4h 0.13-0.38mg/L
Rat Dermal LD50 61-185mg/kg

Sodium Metavanadate

Rat Oral LD 50 98

Sodium Selenate

Rat Oral LD 50 1600

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 14 of 24
Version: 1.1

11. TOXICOLOGICAL INFORMATION

Butylated hydroxytoluene

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Moderate

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating

POTASSIUM CHLORIDE

Eye Irritation Rabbit Mild

Zinc oxide

Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Polyethylene glycol

Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Butylated hydroxytoluene

4 Week(s) Rat Oral 5185 mg/kg LOAEL Liver
4 Day(s) Mouse Oral 2000 mg/kg LOAEL Liver, Kidney, Ureter, Bladder

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Butylated hydroxytoluene

Embryo / Fetal Development Rat Oral 6 g/kg LOEL Teratogenic,

Cholecalciferol (Vitamin D3)

Embryo / Fetal Development Rat Subcutaneous 90 mg/kg/day LOEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Cholecalciferol (Vitamin D3)

In Vitro Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Butylated hydroxytoluene

IARC: Group 3 (Not Classifiable)

Crospovidone

IARC: Group 3 (Not Classifiable)

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 15 of 24
Version: 1.1

11. TOXICOLOGICAL INFORMATION

Polyvinyl alcohol

IARC: Group 3 (Not Classifiable)

Talc (non-asbestiform)

IARC: Group 3 (Not Classifiable)

Titanium dioxide

IARC: Group 2B (Possibly Carcinogenic to Humans)

Phytonadione (Vit.K)

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

POTASSIUM CHLORIDE

Gambusia affinis (Mosquitofish) LC50 96 Hours 920 mg/L
Lepomis macrochirus (Bluegill Sunfish) LC50 96 Hours 2010 mg/L
Daphnia Magna (Water Flea) EC50 48 Hours 825 mg/L
Scenedesmus subspicatus (Green Alga) EC50 72 Hours 2500 mg/L

Zinc oxide

Tadpole EC50 48 Hours 3.2 mg/L

Cupric sulfate

Daphnia magna (Water Flea) EC50 48 Hours 0.024 mg/L
Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours 0.1 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 16 of 24
Version: 1.1

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. This product may qualify as a RCRA Hazardous Waste. Status should be confirmed by testing for RCRA hazardous characteristics (i.e. corrosivity, toxicity, reactivity, or ignitability).

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Ferrous fumarate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	205-447-7

Maltodextrin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-940-4

Ascorbic acid (Vitamin C)

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 17 of 24
Version: 1.1

15. REGULATORY INFORMATION

EU EINECS/ELINCS List	200-066-2
Beta Carotene	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	230-636-6
Biotin	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-399-3
Butylated hydroxytoluene	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	204-881-4
Calcium carbonate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	207-439-9
Calcium pantothenate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	205-278-9
Cholecalciferol (Vitamin D3)	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 7
EU EINECS/ELINCS List	200-673-2
POTASSIUM CHLORIDE	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 18 of 24
Version: 1.1

15. REGULATORY INFORMATION

Australia (AICS): Standard for the Uniform Scheduling for Drugs and Poisons: EU EINECS/ELINCS List	Present Schedule 4 231-211-8
Chromium picolinate CERCLA/SARA 313 Emission reporting California Proposition 65 EU EINECS/ELINCS List	Not Listed Not Listed Not Listed
Corn Starch CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): REACH - Annex IV - Exemptions from the obligations of Register: EU EINECS/ELINCS List	Not Listed Not Listed Present Present Present 232-679-6
Cupric sulfate CERCLA/SARA 313 Emission reporting CERCLA/SARA Hazardous Substances and their Reportable Quantities: California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): Standard for the Uniform Scheduling for Drugs and Poisons: EU EINECS/ELINCS List	Not Listed 10 lb 4.54 kg Not Listed Present Present Schedule 6 231-847-6
Crospovidone CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present Present Not Listed
Cyanocobalamin (Vitamin B12) CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present Present 200-680-0
Dicalcium Phosphate CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present Present 231-826-1
Polyvinyl alcohol CERCLA/SARA 313 Emission reporting	Not Listed

SAFETY DATA SHEET

Material Name: **CENTRUM Men Tablets**
 Revision date: 02-Feb-2016

Page 19 of 24
 Version: 1.1

15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
FD & C Red No. 40, aluminum lake	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	271-524-7
FD&C yellow No.6 aluminum lake	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	239-888-1
Stannous Chloride	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Folic Acid	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 2 Schedule 4
EU EINECS/ELINCS List	200-419-0
Gelatin	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-554-6
Hydrogenated Palm Oil	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	271-056-3
Lecithin	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 20 of 24
Version: 1.1

15. REGULATORY INFORMATION

Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-307-2
Lycopene	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	207-949-1
Polyethylene glycol	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 3
EU EINECS/ELINCS List	Not Listed
Magnesium oxide	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-171-9
Magnesium stearate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3
Manganese sulfate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-089-9
Microcrystalline cellulose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex XVII - Restrictions on Certain Dangerous Substances:	Use restricted. See item 9[f]. powder
EU EINECS/ELINCS List	232-674-9
Niacinamide	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
 Revision date: 02-Feb-2016

Page 21 of 24
 Version: 1.1

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-713-4
Nickel sulphate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
REACH - Annex XVII - Restrictions on Certain Dangerous Substances:	Use restricted. See item 27.
REACH - Carcinogens Category 1:	Present
REACH - Toxic to Reproduction Category 2:	Present
EU EINECS/ELINCS List	Not Listed
Phytonadione (Vit.K)	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-564-2
Potassium Iodide	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-659-4
Pyridoxine Hydrochloride (Vitamin B6)	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-386-2
Riboflavin (Vitamin B2)	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-507-1
Silicon dioxide, NF	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-545-4
Sodium ascorbate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 22 of 24
Version: 1.1

15. REGULATORY INFORMATION

Australia (AICS):	Present
EU EINECS/ELINCS List	205-126-1
Sodium Metavanadate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	237-272-7
Sodium Molybdate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-551-7
Sodium Selenate	
CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	100 lb 10000 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	100 lb
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-501-8
Talc (non-asbestiform)	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	238-877-9
Thiamine Mononitrate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	208-537-4
Titanium dioxide	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 9/2/11 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5
Tocopherols	
CERCLA/SARA 313 Emission reporting	Not Listed

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 23 of 24
Version: 1.1

15. REGULATORY INFORMATION

California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Vitamin A Acetate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	204-844-2

Vitamin E, dl-tocopheryl acetate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	257-757-7

Zinc oxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-222-5

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Acute toxicity, dermal-Cat.3; H311 - Toxic in contact with skin
Specific target organ toxicity, repeated exposure-Cat.1; H372 - Causes damage to organs through prolonged or repeated exposure
Acute toxicity, inhalation-Cat.2; H330 - Fatal if inhaled
Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects
Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects
Serious eye damage/eye irritation-Cat. 2B; H319 - Causes serious eye irritation
Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure
Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Carcinogenicity-Cat.1A; H350 - May cause cancer by inhalation
Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled
Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled
Skin corrosion/irritation-Cat.2; H315 - Causes skin irritation

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 3 - Composition / Information on Ingredients.

Revision date: 02-Feb-2016

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

SAFETY DATA SHEET

Material Name: CENTRUM Men Tablets
Revision date: 02-Feb-2016

Page 24 of 24
Version: 1.1

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet